Evolus focuses on enhancing the beauty experience through innovative products and consumer engagement strategies. One of their key offerings is Jeuveau, a neuromodulator specifically designed for aesthetic use, which aims to reduce the appearance of fine lines and wrinkles. The company emphasizes the importance of clinical studies that support the efficacy and safety of their products, ensuring that consumers receive reliable and effective treatments. Additionally, Evolus has developed the Evolus Rewards™ program, a unique patient loyalty initiative that incentivizes consumers by providing discounts on treatments, thereby fostering a strong relationship between the company and its clientele.

The company is committed to making beauty treatments accessible and rewarding for consumers, as evidenced by their one million enrolled members in the Evolus Rewards program. This program not only offers financial benefits, such as $40 off every treatment, but also encourages regular engagement with their products. Evolus aims to create a delightful experience for consumers while supporting practices in growing their patient base through these rewards. Overall, Evolus combines advanced scientific research with consumer-focused initiatives to redefine the beauty treatment landscape.

United States

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Skin Diseases

Evolus

Benign tumor

Glabellar lines

<p class="font_7">JEUVEAU blocks neuromuscular transmission by binding to acceptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. When injected intramuscularly at therapeutic doses, JEUVEAU produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity.</p>

Evolus

Company Details